Research is under way on the effectiveness of treating addiction with these medications, and some initial studies have shown promising results
But there are exceptions: Compounding pharmacies can fill the gap when a drug is in shortage
The same way we manage risk with psychiatric medications that have serious potential side effects
More recently, with a better risk factors control, mainly in intensive LDL cholesterol targets with statins, a significant decrease in acute cardiovascular events was observed in diabetic population
Semaglutide selectively activates the GLP-1 receptor, producing: Glucose-dependent insulin secretion : Reduces hypoglycemia risk compared to non-incretin agents Glucagon suppression : Reduces hepatic glucose output in the hyperglycemic state Gastric emptying delay : Contributes to postprandial glucose control and satiety Central appetite regulation : Acts on GLP-1 receptors in the hypothalamus and brainstem to reduce hunger and alter food preferences The simplicity of semaglutide's single-receptor mechanism is both a limitation (no energy expenditure enhancement from glucagon) and a strength (thoroughly understood pharmacology, predictable effects, extensive safety characterization)
Its involvement at the intersection of metabolic regulation, stress responsiveness, and reproductive endocrinology positions it as a candidate for conditions in which these domains converge, such as menopause-associated metabolic dysfunction or stress-related eating disorders
